Prescient Therapeutics (ASX:PTX) starts enrolling patients for extended PTX-100 trial for lymphomas

Follow us on Google News:
 Prescient Therapeutics (ASX:PTX) starts enrolling patients for extended PTX-100 trial for lymphomas
Image source: © Convisum | Megapixl.com

Highlights 

  • PTX aims to complete the recruitment of the expansion cohort by the end of 2022
  • There have been already two unexpected and stunning responses in the prior cohort of PTX-100 in T-cell lymphomas
  • One PTCL patient in previous escalation cohort remains on PTX-100 with durable partial response for 24 months to date

Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment in the expansion cohort of the Phase 1b trial of PTX-100 to treat lymphomas.

Lymphomas refer to a group of aggressive and rare blood cancers with high unmet clinical need.

The expansion will enrol 8 to 12 patients with relapsed and refractory T-cell lymphoma. It is an open-label, non-randomised study led by a world-renowned hematologist, Professor H. Miles Prince, at Epworth hospital in Melbourne.

On back of this news, PTX shares closed 3.3% higher at AU$0.155 on the ASX on 5 April 2022.  

Prescient is developing a personalised medicine approach for cancer, including targeted and cellular therapies. PTX-100 is a first-in-class targeted therapy that blocks a vital cancer growth enzyme called GGT-1. It was co-invented by Prescient’s Scientific Founder, Professor Said Sebti, and is exclusively licensed by Prescient from Yale University.

Do read: Prescient Therapeutics (ASX: PTX) achieves significant milestones in 2021

Investigation being carried out in lab

Image source: © Elnur | Megapixl.com

‘Encouraging preliminary evidence’ for PTX-100

The Phase 1b study in patients with T-cell lymphomas demonstrated excellent safety data and encouraging preliminary evidence of clinical efficacy for PTX-100. This prompted clinical investigators to recommend expanding the study and focusing on enrolling patients with T-cell lymphomas (PTCL).

What is Peritoneal T-Cell Lymphoma (PTCL)?

PTCL is a blood cancer with a substantial unmet need for new therapies and PTX believes that this represents an exciting clinical and commercial opportunity for PTX-100. Prescient also plans to include several patients with cutaneous T-cell lymphoma (CTCL). CTCL clinical samples will strengthen insights on drug action in T-cell lymphomas overall.

Related read: Prescient Therapeutics’ (ASX:PTX) 1H22 marked by key clinical milestones

In both cases, such patients with refractory T-cell lymphomas on standard treatments would typically be anticipated to have disease progression within four months. This signifies the encouraging nature of response to PTX-100.

Also read: Prescient Therapeutics (ASX: PTX) tables impressive results for December quarter

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK